Pantop%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520ds

# Pantoprazole ## Overview Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion. ## Primary Indications * Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD). * Reduction of daily doses of long-term maintenance therapy of healing erosive esophagitis. * Pathological hypersecretory conditions, including Zollinger-Ellison syndrome. ## Adult Dosing * **Erosive Esophagitis:** 40 mg once daily for up to 8 weeks. A subsequent 8-week course may be considered for patients who have not healed. * **Maintenance of Healing Erosive Esophagitis:** 40 mg once daily. * **Pathological Hypersecretory Conditions (e.g., Zollinger-Ellison Syndrome):** Starting dose of 40 mg twice daily. Doses may be titrated up to 240 mg daily depending on patient response. Doses greater than 80 mg daily should be administered in divided doses. ## Pediatric Dosing * **GERD and Erosive Esophagitis (1-5 years):** 10 mg once daily. * **GERD and Erosive Esophagitis (5-12 years):** 20 mg once daily. * **GERD and Erosive Esophagitis (12 years and older):** 40 mg once daily. * *Dosing for Zollinger-Ellison syndrome in pediatrics is not established.* ## Dose Adjustments * **Hepatic Impairment:** Maximum dose of 40 mg once daily. * **Renal Impairment:** No dose adjustment necessary. ## Contraindications * Known hypersensitivity to any component of the formulation or to any substituted benzimidazole. ## Adverse Effects Common adverse effects include headache, diarrhea, nausea, abdominal pain, and dizziness. Long-term use of PPIs may be associated with an increased risk of fractures, Clostridium difficile infection, hypomagnesemia, and vitamin B12 deficiency. ## Key Drug Interactions * **Drugs Dependent on Gastric pH for Absorption:** Ketoconazole, itraconazole, iron salts, mycophenolate mofetil. Monitor for decreased efficacy. * **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity. Consider interruption of pantoprazole or dose reduction of methotrexate if clinically indicated. * **CYP2C19 Substrates:** Pantoprazole can inhibit CYP2C19, potentially increasing concentrations of drugs like clopidogrel. ## Monitoring * Monitor for signs and symptoms of hypomagnesemia (e.g., tremor, tetany, seizures) with prolonged use. * Monitor bone mineral density in patients at risk for osteoporosis. * Assess for effectiveness and need for continued therapy. ## Clinical Pearls * Administer pantoprazole orally 30 minutes before a meal. * For IV administration, reconstitute and dilute according to manufacturer instructions. * Consider the risks and benefits of long-term PPI therapy, especially in elderly patients and those with risk factors for osteoporosis or fracture. *** *This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always verify current prescribing information with the manufacturer's package insert or a reliable drug information resource.*